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Abstract
A nanosuspension (NS) was formulated from the lipophilic molecule cholecalciferol (CL) for
enhanced transdermal delivery by embedding this NS into hydrophilic polymer-based dis-
solving microneedles (DMNs). First, the NS was prepared by sonoprecpitation with differ-
ent molecular weights of poly (vinyl alcohol) and poly (vinyl pyrrolidone) as stabilizers
and using two different solvents for particle size and zeta potential optimization. DMN ar-
rays were then prepared by centrifugation-assisted micromoulding and subsequently
dried. Poly (vinyl alcohol) (10 kDa) produced a NS with the lowest particle size ( ̴
300 nm). These particles yielded DMN with good mechanical properties when combined
with aqueous blends of high molecular weight poly (vinyl pyrrolidone) (360 kDa). The par-
ticle size remained similar before and after MN preparation, as conﬁrmed by scanning
electron microscope. The CL was in the amorphous state in the free particles as well as
in the DMN and, hence, no characteristic CL peak was observed in differential scanning cal-
orimetry or X-ray diffraction. DMN arrays were found to be strong enough to bear a 32 N
force, showed efﬁcient skin insertion, and penetrated down to the third layer
(depth ≈ 375 μm) of the validated skin model Paraﬁlm M®. An ex vivo porcine skin perme-
ation study using Franz diffusion cells compared the permeation of CL from CL-NS-loaded
DMN arrays and MN-free CL-NS patches. It was observed that CL-NS-loaded DMN arrays
showed signiﬁcantly higher (498.19 μg ± 89.3 μg) ex vivo skin permeation compared with
MN-free CL-NS patches (73.2 μg ± 26.5 μg) over 24 h. This is the ﬁrst time a NS of a hydro-
phobic drug has been successfully incorporated into dissolving MN and suggest that NS-
containing DMN systems could be a promising strategy for transdermal delivery of hydro-
phobic drugs.
© 2018 The Authors. Journal of Interdisciplinary Nanomedicine published by John Wiley & Sons Ltd and the British Society for Nanomedicine
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Introduction
Microneedle (MN) arrays have been extensively
researched in the last two decades to bridge the
substantial gap between transdermal patches and
pain-causing injections. MNs are minimally invasive,
pain-free, micron-sized projection arrays (10 μm
900 μm) on baseplates capable of piercing the skin’s
stratum corneum, overcoming its barrier properties to
create a transport pathway for drug molecules. MN has
been shown to be suitable for self-administration by
patients (Kaushik et al., 2001; Prausnitz, 2004;
Vicente-Prez et al., 2016). A vast array of different MN
types have been studied, including solid MN (Henry,
McAllister, Allen, & Prausnitz, 1998), drug-coated MN
(McGrath et al., 2011), and dissolving MN (DMN).
The disadvantage associated with solid MN used for
pretreatment of skin is that the holes generated are
quickly closed, resulting in reduced drug permeation.
Drug-coated MN can lose sharpness after coating, the
loaded dose is understandably small, and sustained
delivery is not achievable. Both the aforementioned
MN types generate potentially biohazardous sharp
waste products. On the contrary, DMNs are fabricated
by using water-soluble biodegradable polymers that
completely dissolve or degrade in the skin, releasing
the drug. This also eliminates any potential risk of
biohazardous sharp waste. Sustained delivery from the
MN baseplates is also possible for small molecules
(Wu et al., 2015). DMN has been widely used to deliver
hydrophilic drugs, as such molecules are easy to mix
with water-soluble polymers used for DMN preparation
(Donnelly et al., 2011). Due to their insolubility in the
aqueous blends typically used to cast DMN and, perhaps,
a concern over solubility in skin interstitial ﬂuid,
lipophilic molecules have not typically been loaded into
DMN. However, approximately 40% of new pharmaceuti-
cal drugs are which makes their efﬁcient delivery
using conventional dosage forms problematic (Dahan &
Hoffman, 2008).
Dissolving microneedles efﬁciently deliver
therapeutic agents through the dissolution of their
biocompatible polymer matrices after penetration into
the skin (Vora, Donnelly, et al., 2017; Vora, Sita, &
Vavia, 2017). DMNs rely on the water solubility of both
the loaded drug and the polymer matrix. Development
of DMN for lipophilic drugs may be a challenging task,
as the drug may not be uniformly dispersed in aqueous
casting blends and, hence, it may be difﬁcult to load
high amounts of the drug. To facilitate solubilization
of lipophilic drugs, organic solvents may be used. This
can potentially lead to nonhomogeneity due to
aggregation of the hydrophilic matrix-forming polymer.
The use of organic solvents can also weaken the DMN
structure, as they can generate pores in the hydrophilic
polymer matrix (Dangol et al., 2016).
To overcome these limitations, nanoparticles can be
considered. Nanoparticles necessitate the use of high
amounts of lipidic or polymeric excipients to
encapsulate the drug, resulting in lower drug load in
the ﬁnal dosage form (Jain, Patel, Shah, Khatri, & Vora,
2016; Lai et al., 2013). The size reduction of micron-
size hydrophobic drugs to submicron size, so-called
nanosuspensions (NSs), represents an exciting colloidal
delivery system (Müller & Peters, 1998).
Nanosuspensions are pure forms of drug nanoparticles
without any polymeric or lipidic matrix, except small
amounts of stabilizer that surrounds a solid drug core.
NSs, therefore, yield high drug loadings (Date &
Patravale, 2004).
Particle size reduction to below 1 μm leads to
increase in the surface-to-volume ratio of nanocrystals
and an increase in aqueous solubility, as well as
dissolution rate of hydrophobic molecules. NSs have
been extensively explored for parenteral (Wong et al.,
2008), oral (Kesisoglou, Panmai, & Wu, 2007), ocular
(Kassem, Abdel Rahman, Ghorab, Ahmed, & Khalil,
2007), and pulmonary routes of application but have
not been considered in detail for transdermal delivery,
probably because intact particles are known not to
efﬁciently traverse the stratum corneum. If pure drug
nanoparticles could be deposited as a depot y DMN
and rapidly dissolve in skin interstitial ﬂuid, allowing
absorption by the rich dermal microcirculation, then
therapeutic plasma levels can possibly be achieved.
(Donnelly & Larrañeta, 2017).
To explore this concept of NS loaded in DMN,
cholecalciferol (vitamin D3) was used as a model
lipophilic molecule. Vitamin D deﬁciency and its
relationship with many diseases have become a major
topic of medical and scientiﬁc discussion. Vitamin D
is obtained from the skin’s exposure to natural
sunlight. Increasing vitamin D deﬁciency in urban
populations is due to limited sun exposure (Kannan &
Lim, 2013).
For oral vitamin D delivery, there are many
challenges, including chemical instability and poor
solubility in the gastrointestinal tract, as well as
signiﬁcant ﬁrst-pass metabolism, which prevents the
drug from reaching the systemic circulation in its active
form (Grossmann & Tangpricha, 2010). To overcome this
Nanosuspension, dissolving microneedles Lalit K. Vora et al.
2018 | Volume 3 | Issue 2 |
Page 90
oral bioavailability issues and to mimic the physiologi-
cal condition of vitamin D synthesis in the skin, it could
be delivered transdermally. To circumvent the signiﬁ-
cant barrier of the stratum corneum, cholecalciferol
nanosuspension (CL-NS)-loaded DMNs were developed
and characterized here. For this purpose, ﬁrst CL-NS
was prepared by a sonoprecipitation method. CL-NSs
were optimized for particle size and, subsequently,
loaded inside DMN by single-step centrifugation. The
developed CL-NS-loaded DMNs were tested for content
uniformity, particle size, and ex vivo porcine skin
permeation.
Materials and Methods
Materials
Cholecalciferol (CL, 99% purity), poly (vinyl alcohol)
(PVA) (10, 31–50, and 120 kDa), poly (vinyl pyrrolidone)
(PVP) (10, 40, and 360 kDa), D-α-tocopherol succinate
(TS), acetonitrile, and methanol (both of high-
performance liquid chromatography (HPLC) grade)
were all purchased from Sigma Aldrich (Poole, Dorset,
UK). All other chemicals used were of analytical grade.
Millipore HPLC-grade water was used throughout the
study.
Preparation and optimization of cholecalciferol
nanosuspensions
Cholecalciferol nanosuspensions were prepared by a
solvent evaporation antisolvent precipitation method
employing probe sonication. Acetone and ethanol were
selected as solvents based on the solubility of CL. CL
(50 mg) and TS (20 mg) were dissolved in 1 mL of etha-
nol or acetone. The different molecular weights (MWs)
of PVA or PVP were dissolved separately in water to pre-
pare 2% w/v solutions. The drug solution was added
dropwise over 1 min into the stabilizer solution (3 mL)
under probe sonication (QS4 system, NanoLab, Wal-
tham, MA, USA) that was continued for 5 min at an am-
plitude of 80% (of 125 W, 20 KHz) with 10 sec pulse on
and 5 sec pulse off. The temperature of the stabilizer
solution was maintained at 5°C ± 3°C during sonication.
This drug dispersion was then allowed to precipitate in
nanosize by solvent evaporation at ambient tempera-
ture conditions with magnetic stirring (Fig. 1).
Effect of polymer concentration, drug concentration
in a solvent, the solvent to antisolvent ratio, and soni-
cation amplitude on particle size and particle size dis-
tribution (polydispersity index, PDI) were evaluated as
per Table 1. To get the powder form of optimized CL-
NS for instrumental characterization, CL-NS were
Figure 1. Schematic representation of fabrication of nanosuspensions and nanosuspension-loaded microneedle arrays. PVA, poly (vinyl al-
cohol); PVP, poly (vinyl pyrrolidone).
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prefrozen (70°C) for 12 h and subsequently
lyophilized for 8 h with hold and ramp cycles from
40°C to 25°C.
Particle size analysis and surface charge
measurement
The hydrodynamic diameter (z-average, z-ave) of the
NS was determined by dynamic light scattering, using
a Zetasizer™ Nano SZ (Malvern Instruments,
Worcestershire, UK). Particle size by dynamic light
scattering gives the hydrodynamic radius of particles.
The results are the z-average, which is the intensity-
weighted mean diameter of the bulk population and
the PDI, which is a measure of the width of the size dis-
tribution. Samples were diluted in water to a suitable
concentration prior to analysis. The Zetasizer™ was also
used for measurement of zeta potential. Zeta potential
was measured by applying an electric ﬁeld across the
CL-NS solutions using the technique of laser doppler an-
emometry. All measurements were carried out at
25 ± 2°C using folded capillary cells.
Cholecalciferol nanosuspension-loaded
dissolving microneedle preparation
Dissolving microneedle arrays were prepared using the
same MW polymers that were used for CL-NS prepara-
tion. DMN arrays were prepared by centrifugation-
assisted micromoulding and subsequently dried as de-
scribed previously (Donnelly et al., 2011) (Fig. 1). In de-
tail, 3 mL of NS containing 50 mg of drug was added to
3 mL of polymeric solution, as detailed in Table 2. The
homogeneity of the NS was ensured by mixing the sus-
pension carefully for 10 min before DMN casting. Ap-
proximately 500 mg from the resulting NS-loaded gel
solution was poured into laser-engineered poly
(dimethylsiloxane) mould templates (19 × 19 and
12 × 12), centrifuged at 3500 RPM for 15 min followed
by drying under ambient condition for 48 h. DMN arrays
were then removed from the moulds and visually
assessed for needle formation and homogeneity. To in-
crease the loading of CL-NS in DMN after initial optimi-
zation of polymer content, the evaporation step during
CL-NS manufacture was carried out for a longer time
and at 35°C to yield approximately 30% of the initial
volume and then mixed with an equal volume of 30%
w/v PVP gel for further DMN preparation. DMN-free
patches (baseplates) were prepared by the same
method, except using micromoulds with no projections.
High-performance liquid chromatography
analysis
Analysis of CL was performed using reversed-phase
HPLC (Agilent 1200® Binary Pump, Agilent 1200®, Stan-
dard Autosampler, Agilent 1200® Variable Wavelength
Detector; Agilent Technologies UK Ltd., Stockport, UK)
with the detection wavelength set at 265 nm. Chro-
matographic separation was carried out with a Luna C
(150 × 4.6 mm 18 (ODS1) column i.d. with 5 μm packing;
Phenomenex, Macclesﬁeld, UK) with 1-mL/min
isocratic elution. The mobile phase was a mixture of
acetonitrile: methanol: water (90:8:2 v/v/v). Standard
solutions of CL were prepared by diluting appropriate
volumes of a stock solution of CL in methanol to give ﬁ-
nal concentrations of 0.1, 0.2, 0.5, 1, 2, 5, and
10 μg/mL. Then, 20 μL of each solution was injected
onto the HPLC.
Drug content and content uniformity
Drug content was analysed by dissolving accurately
weighed CL-NS-loaded DMN arrays in 2-mL water: etha-
nol (30:70) mixture and collecting 100 μL into 1.5-mL
tubes. This was then mixed with 0.9-mL acetonitrile
to allow precipitation of PVP polymer while the drug
remained dissolved. This dispersion was centrifuged at
12,000 × g for 10 min, and the supernatant was col-
lected for HPLC analysis. The content uniformity test
was performed to investigate whether there was a uni-
form distribution of drug or drug NS within individual
DMN arrays. For content uniformity within an individual
DMN, percent drug recovery was determined from
Table 1. Inﬂuence of different formulation parameters on parti-
cle size and PDI value of CL-NS.
PVA conc.
(% w/v)
Solvent to
antisolvent
ratio
Sonication
amptitude
(%)
Drug
conc.
(mg/mL)
0.5 0.33 80 50
1 0.33 80 50
2 0.33 80 50
2 0.55 80 50
2 0.66 80 50
2 1 80 50
2 0.33 40 50
2 0.33 20 50
2 0.33 80 30
2 0.33 80 25
2 0.33 80 12.5
CL-NS, cholecalciferol nanosuspension; PDI, polydispersity index; PVA, poly
(vinyl alcohol).
Nanosuspension, dissolving microneedles Lalit K. Vora et al.
2018 | Volume 3 | Issue 2 |
Page 92
three different surface areas of the DMN, needles,
baseplate, and the “sidewalls” formed during
micromoulding (Donnelly et al., 2011) by following the
same procedure as for drug content analysis. Studies
were done in triplicate for each concentration. For con-
tent uniformity comparison, plain (non-NS) CL-loaded
DMN arrays were prepared.
Mechanical and insertion properties of
cholecalciferol nanosuspension-loaded
dissolving microneedle arrays
A TA.XT-Plus Texture Analyser (Stable Microsystem,
Haslemere, UK) was used in compression mode to assess
the compression and insertion properties of the NS-
loaded DMN arrays (Quinn et al., 2015). Initial heights
of DMN were ﬁrst determined using a stereo micro-
scope. Then, CL-NS-loaded DMN arrays were attached
using double-sided adhesive tape to the movable cylin-
drical probe of the Texture Analyser and pressed by the
test station against a ﬂat aluminium block at a rate of
0.5 mm/sec for 30 sec and a force of 32 N (0.088 N/nee-
dle) (Eltayib et al., 2016). Pretest and posttest speeds
were set at 1 mm/sec, and the trigger force was set
at 0.049 N. DMN heights were measured again using
the stereo microscope, and the percentage reduction
in height following the application of the axial com-
pression load was calculated. To determine insertion
properties of the DMN arrays, Paraﬁlm M® (Bemis Com-
pany Inc., Soignies, Belgium), a ﬂexible thermoplastic
sheet made of oleﬁn-type material was used. Paraﬁlm
M® has been previously validated as a skin simulant
for insertion of MN (Larrañeta et al., 2014). The initial
heights of the DMN arrays were measured microscopi-
cally prior to the test. The Paraﬁlm M® sheet was
folded into an eight-layer ﬁlm (1 mm thickness). Fol-
lowing attachment of the MN array to the movable
probe of the Texture Analyser, the probe was lowered
onto the folded Paraﬁlm M® at a speed of 1.19 mm/
sec until the required force of 32 N was exerted and
held for 30 sec. The MN were then removed from the
Paraﬁlm M® sheet after insertion. The Paraﬁlm M®
sheet was unfolded, and the number of holes in each
layer counted. The retrieved DMN had their heights
evaluated using a Leica EZ4 D digital microscope (Leica
Microsystems, Wetzlar, Germany).
Microscopic analysis of cholecalciferol
nanosuspension-loaded dissolving microneedle
arrays
The surface morphology and shape of CL-NS-loaded
DMN arrays were examined by using a Keyence VHX-
700F Digital Microscope (Keyence, Osaka, Japan) and
a TM3030 benchtop scanning electron microscope
(SEM) (Hitachi, Krefeld, Germany). The latter was used
in low vacuum mode at a voltage of 15 kV. In the case of
NS particles, visualization inside the DMN arrays was
achieved by SEM with a Quanta FEG 250 (FEI, Hillsboro,
OR, USA) at an acceleration voltage of 10–20 kV under
high chamber pressure (8 × 105 mbar) with standard
SEM carbon tape as background.
Differential scanning calorimetry analysis
Differential scanning calorimetry (DSC) studies of CL,
TS, physical mixture, and CL-NS-loaded DMN arrays
were carried out with a DSC Q100 (TA Instruments, Sur-
rey, United Kingdom). Sample weights of 4.0–5.0 mg
were sealed in nonhermetic-type aluminium pans and
ramped at a heating rate of 10.0°C/min in nitrogen at
a ﬂow rate of 50.0 mL/min. The DSC was calibrated
with the melting temperature of indium (156.6°C).
X-ray diffraction measurements
The study was carried out using a benchtop X-ray dif-
fractometer (Miniﬂex™, Rigaku, Neu-Isenburg,
Germany). Radiation was from Ni-ﬁltered CuK, with a
wavelength of 1.54 A° having a graphite
Table 2. Formulation parameters for CL-NS-loaded DMN with different molecular weights of PVP and PVA.
Drug with stabilizer Solvent (1 mL) 2% w/v Polymer (3 mL) Mixing with 3-mL polymer gel (% w/v) for MN
50 mg CL +20 mg TS Acetone PVA, 10 kDa 60% PVA. 10 kDa
PVA, 50 kDa 40% PVA, 50 kDa
PVA, 120 kDa 20% PVA, 120 kDa
50 mg CL +20 mg TS Ethanol PVP, 10 kDa 60% PVP, 10 kDa
PVP, 40 kDa 40% PVP, 40 kDa
PVP, 360 kDa 30% PVP, 360 kDa
CL-NS, cholecalciferol nanosuspension; DMN, dissolving microneedle; PVA, poly (vinyl alcohol); PVP, poly (vinyl pyrrolidone); TS, tocopherol succinate.
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monochromator. CL, TS, PVP plain polymer, CL-NS-
loaded PVP DMN, and physical mixture of CL, TS, and
PVP were respectively packed into the rotating sample
holder. The obtained data were typically collected by
scanning a range of 0–50°, with a scanning rate of
2°/min.
Determination of skin penetration by optical
coherence tomography
Full-thickness neonatal porcine skin, a good model for
human skin (Cilurzo, Minghetti, & Sinico, 2007; Simon
& Maibach, 2000; Touitou, Meidan, & Horwitz, 1998),
was used to study insertion of CL-NS-loaded DMN. The
skin was obtained from stillborn piglets and excised
within 24 h of birth using an electric dermatome
(Integra Life Sciences™, NJ, USA). The skin was then
wrapped in aluminium foil and stored at 20°C until
use. After thawing in phosphate-buffered saline (PBS)
(pH 7.4), the skin was carefully shaved and washed with
PBS before use. The skin surface was dried using tissue
paper and placed dermis side down on a dental wax
sheet. DMN arrays were then inserted using the Texture
Analyser, with force of 32 N for 30 sec. Optical coher-
ence tomography (OCT) images were recorded using
an EX1301 OCT Microscope (Michelson Diagnostics
Ltd., Kent, UK).
Ex vivo porcine skin permeation of
cholecalciferol from cholecalciferol
nanosuspension-loaded dissolving microneedle
arrays
Permeation of CL-NS-loaded DMN arrays across
dermatomed (350 μm) neonatal porcine skin was inves-
tigated ex vivo using modiﬁed Franz diffusion cells, as
described previously (Quinn et al., 2015). The neonatal
porcine skin was excised as aforementioned and
trimmed to a thickness of 350 μm using the electric der-
matome. The skin was again stored in aluminium foil at
20°C until further use. Before use, the skin was
bathed in PBS to thaw and, once defrosted, carefully
shaved. Sections of skin were cut by scalpel to match
the diameter of the Franz cell donor compartments
and carefully afﬁxed to the donor compartment on
the stratum corneum side using cyanoacrylate adhesive
(Loctite, Dublin, Ireland), rendering the SC available
for MN application. For the CL-NS-loaded DMN arrays
(12 × 12 needle density, 600 μm height, 300 μm width
at the base, and 150 μm interspacing), DMN was re-
moved from the mould by gently squeezing the corners
of the mould and sidewalls of the array were removed
using a heated scalpel blade. CL-NS-loaded DMN arrays
were then inserted using manual pressure for 30 sec ap-
plied to the MN baseplate. A cylindrical 5.0-g stainless
steel weight was placed on top of the DMN array to pre-
vent MN expulsion, and the donor compartment of the
apparatus was clamped onto the receiver compartment
and sealed using Paraﬁlm M®. The receiver compart-
ment contained 12-mL PBS with 2% v/v Tween 80 to
maintain solubility of the drugs in the receiver com-
partment and ensure sink conditions. Syringes
(1.0 mL) with long needles were used to remove
200 μL from the Franz cell contents at appropriate time
points and 200 μL of prewarmed PBS was added to re-
place this. Samples were stored in 1.5-mL poly (sty-
rene) tubes. Prior to quantiﬁcation of Franz cell drug
content, samples were centrifuged for 5 min at
12,000 x g using an Eppendorf Minispin centrifuge
(Eppendorf UK Ltd, Stevenage, UK). All samples were
analysed using the developed reverse phase-HPLC
method. Permeation from control CL-NS formulations
was performed in the same manner, except instead of
inserting a DMN array, a needle-free patch of the same
dimensions, and formulation was placed on top of the
skin, followed by the stainless steel weight.
Statistical analysis
The results are presented as means ± standard devia-
tion (SD) of the mean. Statistical comparison between
CL-NS-loaded DMN and CL-NS ﬁlms, in terms of CL per-
meation, was made using the Mann–Whitney U-test by
using GraphPad Prism software (ver. 6; GraphPad, Inc.,
San Diego, CA, USA). A difference of p < 0.05 was con-
sidered to be statistically signiﬁcant.
Results and Discussion
Optimization of cholecalciferol nanosuspension
For the ﬁrst time, a CL-NS was prepared by a
sonoprecipitation solvent evaporation method and em-
bedded into DMN arrays. The presence of polymeric sta-
bilizer plays a signiﬁcant role in reduction of particle
size by providing a stearic adsorption barrier on the
particle surface, thus retarding crystal growth or coa-
lescence of individual particles. The ultrasonic energy
created by probe sonication averts a preponderance
of very large particles (Chonkar et al., 2016). Here,
PVP and PVA polymers act as stabilizing agents. As MW
and polymeric chain length are critical factors (Ghosh,
Bose, Vippagunta, & Harmon, 2011), different MWs of
both were studied to ascertain their inﬂuence on
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particle size and zeta potential, as shown in Figure 2.
CL-NS containing lower MW PVA and PVP exhibited
lower particle size, which suggests that these lower
MW polymers are able to form a uniform adsorption
layer on particle surfaces, preventing coalescence of
individual particles. In contrast, high MW PVA and PVP
that most likely possess lower rates of adsorption on
the particle surface yield larger particles. Acetone
was found to yield lower particle sizes with PVA, while
ethanol was found to be a more appropriate solvent
for PVP. CL-NS prepared with 10 kDa PVA produced the
smallest particle size, and these particles also had the
lowest zeta potentials. Because smaller particles are
less likely to disrupt DMN structures following incorpo-
ration, these particles were taken forward for further
DMN development.
After optimization of particle size with PVA (10 kDa),
the effect of formulation variables (Table 1) on particle
size and PDI was evaluated, as shown in Figure 3. PVA
concentration, the solvent to antisolvent ratio, and
sonication amplitude all affected particle size and PDI
values, while drug concentration in solvent had little
effect. Increasing the amount of PVA and amplitude of
probe sonication both decreased the particle size,
while higher CL concentration in solvent and solvent
to antisolvent ratio increased the particle size. PVA
(2% w/v) with 1:3 solvent to antisolvent ratio and 80%
of sonication amplitude for 5 min were found to be op-
timal conditions to attain mean particle size of
305.3 nm ± 32.9 nm and 0.27 ± 0.06 PDI values.
Dissolving microneedles prepared with lower MWs of
PVA (10 kDa, 31–50 kDa) were found to be ﬂexible in na-
ture, while DMNs prepared from higher MW PVA
(120 kDa) were found to be more mechanically strong.
The higher MW PVA was found to be difﬁcult to solubi-
lize and process during DMN preparation. In the case
of PVP, DMNs prepared with lower (10 kDa) and medium
(40 kDa) MW PVP were broken while removing from the
MN mould. DMNs prepared from higher MW (360 kDa)
PVP were found to be more mechanically strong. There-
fore, CL-NS prepared using 10-kDa PVA (302.5 nm) were
mixed with higher MW PVP (30% w/v) gels for DMN array
preparation.
Characteristics of cholecalciferol
nanosuspension-loaded poly (vinyl pyrrolidone)
dissolving microneedle arrays
The digital microscopic images (Fig. 4A and 4B) clearly
showed the formation of CL-NS-loaded PVP DMN arrays
with 12 × 12 and 19 × 19 MN arrays with sharp tips. The
resulting needles measured 600 μm in height with
10% ± 1.6% w/w loading of CL-NS in formulated DMN. As
particle size is an extremely important stability parame-
ter for nanoparticles, particle size was measured before
Figure 2. Effect of polymer molecular weight and solvent on particle size and zeta potential of NS: (A) effect of PVP molecular weight and
solvent on particle size; (B) effect of PVP molecular weight and solvent on zeta potential; (C) effect of PVA molecular weight and solvent
on particle size; (D) effect of PVA molecular weight and solvent on zeta potential (means ± SD, n = 3). PVA, poly (vinyl alcohol); PVP, poly
(vinyl pyrrolidone).
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(297.4 nm ± 20 nm) and after (345.7 nm ± 10.1 nm) MN
preparation. The CL-NS embedded DMN was dispersed
in PBS pH 7.4 buffer without any major changes in parti-
cle size or observation of aggregation. Here, the dried
state of the polymer matrix of DMN possibly acts as a sta-
bilizer for NS particle size, preventing aggregation. The
mean amount of CL recovered from CL-NS-loaded DMN
was 94 ± 5.23%. Content uniformity within single DMN ar-
ray was compared by incorporating plain drug and CL-NS
into dissolving PVP MN arrays. The percentage drug re-
covery with plain CL drug-loaded DMN arrays was
179.3% ± 59%, 75.77% ± 26.6%, and 71.4% ± 16.8% and
with CL-NS-loaded DMN arrays 98% ± 4.5%,
87.5% ± 9.7%, and 106% ± 8.21% for baseplates, side-
walls, and needles, respectively. CL particle aggregation
was visible in plain CL-loaded DMN arrays (Fig. 4C). Rel-
atively lower values of variance for CL-NS-loaded DMN
arrays indicate that drug nanoparticles are uniformly
Figure 3. Inﬂuence of different formulation parameters on particle size and PDI value of CL-NS: (A) effect of PVA concentration; (B) effect
of solvent to antisolvent ratio; (C) effect of CL concentration in solvent; (D) effect of sonication amplitude (means ± SD, n = 3). CL-NS,
cholecalciferol nanosuspension; PDI, polydispersity index; PVA, poly (vinyl alcohol).
Figure 4. Digital microscopic images of CL-NS-loaded DMN arrays: (A) 12 × 12 arrays; (B) 19 × 19 DMN arrays; (C) plain CL loaded-DMN ar-
rays with visible aggregated drug particles; (D) CL-NS-loaded DMN arrays without drug aggregation. CL-NS, cholecalciferol
nanosuspension; DMN, dissolving microneedle.
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distributed in the entire DMN arrays (Fig. 4D). Plain CL-
loaded DMN arrays possessed varied distributions, as
the micron-sized insoluble drug particles aggregated in
the water-based polymer blends during DMN formula-
tion. Therefore, NS is a good approach to uniformly load-
ing lipophilic molecules in hydrophilic polymeric
matrices used for DMN production.
Scanning electron microscopy
Scanning electron microscope images (Fig. 5) showed
spherical particle size of CL-NS. NS embedded in DMN ar-
rays of PVP showed a honeycomb-like matrix with mea-
sured sizes ranging from approximately 100 nm to
around 300 nm. The SEM imaging showed an even distri-
bution of CL-NS in the PVP DMN matrix without any evi-
dent aggregation in different parts of the DMN arrays
(needle tips, near to baseplate, baseplate area). SEM
images taken of plain CL drug-loaded DMN arrays con-
ﬁrmed that there was no evidence of spherical particles.
Mechanical strength and Paraﬁlm insertion of
dissolving microneedle arrays
Following application of the 32 N axial load, the CL-NS-
loaded DMN showed a less than 2% height reduction
(Fig. 6A). The CL-NS-loaded DMN arrays were sufﬁ-
ciently strong to bear the axial mechanical load of
32 N that was previously shown to be the mean force
applied by human volunteers inserting DMN into their
skin (Larrañeta et al., 2014). The same axial force
(32 N) was also applied to evaluate the effects of inser-
tion on needle height, using Paraﬁlm M® as an artiﬁcial
membrane to mimic the skin (Larrañeta et al., 2014).
Figure 5. Scanning electron micrographs of: (A) CL-NS before DMN loading; (B) CL-NS-loaded DMN arrays (12 × 12); (Bi) Magniﬁed image
of tips of DMN arrays; (Bii) Magniﬁed image of a DMN array near the baseplate; (Biii) Magniﬁed image of a DMN array baseplate; (C)
plain CL drug-loaded DMN and magniﬁed image of its needle tips’ surface. CL-NS, cholecalciferol nanosuspension; DMN, dissolving
microneedle.
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The CL-NS-loaded DMN arrays penetrated to the third
layer of Paraﬁlm M® (Fig. 6B). The thickness of each
layer of the Paraﬁlm M® was around 126 μm. Consider-
ing the thickness of each layer of the Paraﬁlm M®, the
total insertion depth was approximately 378 μm, which
equates to more than 60% of the height of the CL-NS-
loaded DMN arrays being inserted without any height
reduction.
Differential scanning calorimetry
The knowledge of the crystalline and amorphous state
of the drug supports understanding of the polymorphic
changes that the drug may have undergone when sub-
jected to nanosizing. Accordingly, it was deemed nec-
essary to study whether the amorphous state was
generated during the production of the NS. DSC ther-
mograms of CL, TS, physical mixtures, and CL-NS-
loaded DMN arrays (Fig. 7) revealed the state of CL-NS
in the DMN. DSC thermograms of pure CL and TS exhib-
ited an intense peak at 87.9°C and 78.33°C, respec-
tively, whereas peaks of CL embedded as NS in DMN
completely disappeared. This suggests that CL in CL-
NS is in the amorphous state in the DMN.
Powder X-ray diffraction
Powder X-ray diffraction studies are used to understand
the nature of core material in polymeric matrices. Pow-
der X-ray diffraction patterns (Fig. 8) of CL exhibited
characteristic crystalline peaks at a 2θ angle of 4.56,
4.8, 13.24, 14.58, 14.86, 17.72, 21.54, 22.64, 26.62,
and 29.6, respectively, indicating its highly crystalline
nature. In contrast, the characteristic drug peaks were
found to be considerably lowered when CL NS was
loaded into DMN, further suggesting that CL was pres-
ent in an amorphous state.
Determination of skin penetration
A non-invasive optical imaging technique, OCT, was
used to acquire real-time images of the insertion of
these CL-NS-loaded DMN arrays into the neonatal por-
cine skin (Fig. 9). These results indicated that DMN ar-
rays possessed the capability to be inserted into the
neonatal porcine skin, reaching insertion depths of ap-
proximately 350–400 μm. The skin insertion proﬁles
Figure 6. (A) Percentage reduction in height of MN upon exertion a force of 32 N at 0.5 m/sec, held for 30 sec (means ± SD, n = 3); (B)
percentage of holes created in each Paraﬁlm M® layer and the corresponding approximate insertion depth, using an insertion force of
32 N for CL-NS-loaded DMN arrays (means ± SD, n = 3). CL-NS, cholecalciferol nanosuspension; DMN, dissolving microneedle.
Figure 7. Differential scanning calorimetry thermograms of the
powder samples of CL, TS, physical mixture, and CL-NS-loaded
DMN arrays. CL-NS, cholecalciferol nanosuspension; DMN, dissolv-
ing microneedle; TS, tocopherol succinate.
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obtained by OCT are consistent with the insertion
depths obtained with Paraﬁlm M® layers. Thus, more
than 60% of the MN height was actually residing within
the skin and, therefore, this was the portion of the
DMN available for in situ dissolution and release of the
nanoparticulate drug intradermally.
Ex vivo porcine skin permeation of
cholecalciferol from cholecalciferol
nanosuspension-loaded dissolving microneedle
arrays
The ex vivo permeation proﬁles of CL across
dermatomed (350 μm) neonatal porcine skin over 24 h
when delivered using CL-NS-loaded DMN arrays and
Figure 8. Powder X-ray diffraction analysis pattern of CL, TS, PVP polymer and physical mixture of CL, TS and PVP, freeze-dried CL-NS, and
CL-NS-loaded DMN arrays. CL-NS, cholecalciferol nanosuspension; DMN, dissolving microneedle; PVP, poly (vinyl pyrrolidone); TS, tocoph-
erol succinate.
Figure 9. Optical coherence tomography images after insertion of
CL-NS loaded DMN arrays into the excised full thickness neonatal
porcine skin in vitro. CL-NS, cholecalciferol nanosuspension;
DMN, dissolving microneedle.
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CL-NS-loaded DMN-free ﬁlms are shown in Figure 10.
Permeation of CL across neonatal porcine skin was sig-
niﬁcantly enhanced by using CL-NS-loaded DMN arrays
in comparison with the CL-NS-loaded DMN-free ﬁlms
(p < 0.05). Following application of the DMN for 24 h,
498.19 μg ± 89.3 μg CL was delivered from CL-NS-
loadedDMNarrays, in comparisonwith 73.2μg ± 26.51μg
delivered from the ﬁlm containing a CL-NS without
DMN. Therefore, the results demonstrate that the CL-
NS-loaded DMN arrays signiﬁcantly assist the delivery
of the CL through the skin to achieve enhanced trans-
dermal delivery. It is likely that nanoformulation en-
hances CL solubility in aqueous ﬂuid relative to the
normal micronized drug particles and that the DMNs al-
low delivery of the nanosized drug by permeating the
stratum corneum barrier. Thereafter, the deposited NS
dissolves in skin interstitial ﬂuid allowing systemic drug
absorption.
Conclusion
This is the ﬁrst time a NS of a hydrophobic drug was suc-
cessfully optimized and incorporated into DMN arrays.
The DMN forming polymer may have acted as a stabi-
lizer for particle size after DMN preparation. NS parti-
cles were uniformly distributed in nanosize without
any aggregation due to the spatial separation of parti-
cles within the polymeric matrix of DMN arrays. This
NS formulation may be able to deliver a wide range of
lipophilic compounds intradermally when combined
with DMN. Such a novel NS-loaded MN system might be
helpful in placing the nanodrug depots into the skin
for enhanced transdermal delivery. Once in the skin,
the solubility-enhancing properties of nanoformulation
should enable drug dissolution in skin interstitial ﬂuid
for subsequent absorption by the rich dermal microcir-
culation. In conclusion, this proof-of-concept work,
therefore, represents a signiﬁcant progression in the
utilization of MN technologies in combination with drug
NSs for delivery of lipophilic drugs into the viable skin
(epidermis and dermis) layers for maximum therapeutic
gain and patient beneﬁt.
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